Requirement for Leucine in Adults Over 60 Years

The Hospital for Sick Children

Status

Completed

Conditions

Healthy

Treatments

Other: Leucine

Study type

Interventional

Funder types

Other

Identifiers

NCT03506126

1000059679

Details and patient eligibility

About

This study aims to determine the requirement for leucine, an essential amino acid, in adults over the age of 60 years. It is known that protein and amino acid metabolism may be altered with age and leucine, in particular, may be important in the diet of older adults.

Eight different levels of leucine intake will be tested in each subject in random order. Each level of leucine intake will involve a 3-day maintenance diet, with measures being collected on the third.

Full description

Leucine is an essential amino acid that is an important component of protein and stimulator of muscle protein synthesis. It is known that as people get older, over the age of 60, our body goes through many changes such as increase in fat mass and decrease in lean mass such as muscle. This is why we are studying how much of the essential amino acid, leucine, the body needs at this particular age.

The indicator amino acid oxidation (IAAO) method is a minimally invasive method for determining essential amino acid requirements.

As essential amino acids cannot be stored in the body, they are either partitioned into protein synthesis or oxidized if in excess. The premise of the IAAO is that when any essential amino acid is limiting in the body then all other amino acids lose their ability to contribute to protein synthesis and are instead oxidized. The method therefore involves providing graded intakes (from deficient to excess) of the test amino acid, leucine, and then measuring the oxidation of another amino acid, which is called the indicator amino acid. This is done by isotopically labelling the indicator amino acid (we often use 13C- phenylalanine) and then measuring the appearance of labelled carbon dioxide (13CO2) in breath with the different intakes of the test amino acid, leucine. The requirement for leucine will be determined by the "breakpoint" - the point at which oxidation of 13C- phenylalanine will plateau.

For the study, subjects will first participate in a pre-study assessment in which height, weight, body composition (fat mass and muscle mass) and resting energy expenditure and medical history will be assessed. Also, 10 ml of blood will be collected to test for diabetes and kidney function. The purpose of the pre-assessment is to calculate subject's dietary requirements for the study, and to assess health status, activity level and dietary patterns.

Subjects will then participate in up to 8 different 3-day studies that will be separated by a minimum of 1 week between each 3-day study. The first 2 days are adaptation days and subjects will consumed the maintenance diet at home s 4 equal meals. The 3rd day is called a study day and subjects will consumed 8 hourly formulas; the first 3 at consumed at home and the remaining 5 are consumed at the Clinical Research Centre at the Hospital for Sick Children. Immediately after the 4th meal, 4 baseline breath and 3 baseline urine samples are collected. After the 5th meal, rate of carbon dioxide production (VCO2) is measured by indirect calorimetry for a period of 20 minutes. The 5th, 6th, 7th, and 8th meal will contain a small amount of isotope labelled phenylalanine (13C phenylalanine). Two and a half hours after the isotope (13C phenylalanine) is given, 4 plateau breath and 3 plateau urine samples are collected.

Breath samples are used to measure the enrichment of isotopic labelled CO2 (13CO2). Urine samples are used to measure the enrichment of isotopic labelled phenylalanine (13C phenylalanine). Through a series of calculations and applying a two-phase regression analysis, we will be able to determine the requirement for leucine.

Enrollment

16 patients

Sex

Male

Ages

60+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy males > 60 years
Willingness to participate in the study and completed the screening procedures (height, weight, fasting blood sample and medical history questionnaire).
No recent history of weight loss
Absence of chronic disease or acute illness that could affect protein and AA metabolism (diabetes, cancer, liver or kidney disease, HIV, acute cold or flu, hypo or hyperthyroidism, rheumatoid arthritis treated with anti-inflammatory medications).
Non-smoking
Willingness to consume the diet provided

Exclusion criteria

Presence of disease known to affect protein and AA metabolism (diabetes, cancer, liver or kidney disease, HIV, acute cold or flu, hypo or hyperthyroidism, rheumatoid arthritis treated with anti-inflammatory medications).
On medications known to affect protein and amino acid metabolism (steroids).
Recent significant weight loss.
Individual on weight reducing diets.
Inability to tolerate the diet
Unwilling to have blood drawn from a venous access, or using a ventilated hood indirect calorimeter for the purposes of the study.
Significant coffee consumption of more than 2 cups/day
Significant alcohol consumption of more than one drink/day